PulmCCM

Share this post
Cochrane review on roflumilast and cilomilast
www.pulmccm.org

Cochrane review on roflumilast and cilomilast

Dec 26, 2011
Share this post
Cochrane review on roflumilast and cilomilast
www.pulmccm.org

Chong J et al review the 23 placebo-randomized trials of just-FDA-approved roflumilast and its sister cilomilast, the oral phosphodiesterase-4 inhibitors. The overall mean improvements in quality of life (1 point on the SGRQ scale) and lung function (46 mL of FEV1) were tiny. The drugs did significantly reduce exacerbations with an odds ratio of 0.78 -- as good or better than currently available inhalers. All the trials were less than one year long. Cochrane Database of Syst Rev 2011;5:CD002309.

Share this post
Cochrane review on roflumilast and cilomilast
www.pulmccm.org
Comments
TopNew

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing